Launches

Ontario provides access to Biktarvy for treatment of HIV

Gilead Sciences Canada announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults. Health Canada granted a Notice of Compliance for BIKTARVY in July 2018.

Alvogen, Lotus launch generic version of Navelbine Softgel capsule in Europe

Alvogen announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe.

Rising Pharmaceuticals announces the US launch of generic version of Pregabalin Capsules

Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, today announced the U.S. launch & commercial shipment of a generic version of Lyrica, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg.

Sun Pharma launches Ezallor Sprinkle in US for people who have difficulty swallowing

Sun Pharmaceutical Industries announced the U.S. launch of Ezallor Sprinkle (rosuvastatin) capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.

Fresenius Kabi introduces Levothyroxine Sodium Injection Solution

Fresenius Kabi has announced tthe immediate availability in the US of Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200 mcg per 5mL and 500mcg per 5mL single-dose vials.

Dr. Reddy’s launches Phytonadione Injectable Emulsion USP, 10 mg/ml single-dose ampules in US

Dr. Reddy’s Laboratories announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, 10 mg/ml, approved by the U.S. Food and Drug Administration (USFDA).

Nektar Therapeutics launches Inheris Biopharma

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.

Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

Teva launches generic version of VESIcare (solifenacin succinate) tablets in US

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.